Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.

Baricitinib is a relatively safe and effective treatment for severe alopecia areata.

Higher Claudin 3 levels in the blood are linked to more severe alopecia areata.

Baricitinib combined with other immune therapies may safely and effectively treat severe scalp hair loss.

Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.

Severe alopecia areata patients have a low chance of spontaneous hair regrowth.

Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.

New mouse models of Pemphigus show severe symptoms and need better treatments.

Intralesional corticosteroids are the best for limited alopecia areata, oral steroids are less effective, and PRP is safe and promising, especially for children and severe cases.

People with alopecia areata have higher levels of osteopontin, which might be important in the disease's development, but this doesn't relate to how severe the disease is.

Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.

AI can accurately measure hair loss severity in alopecia areata.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.

Baricitinib helps long-term hair regrowth in severe alopecia areata patients.

Wigs significantly improve the well-being of people with severe hair loss.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Continued baricitinib treatment leads to significant scalp hair regrowth in severe alopecia areata patients.

Baricitinib 4 mg is effective and safe for treating severe alopecia areata.

Baricitinib effectively regrows hair in most people with severe alopecia, especially those with patchy hair loss, but hair may fall out again if treatment stops.

Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.

Oral betamethasone works faster than oral tofacitinib for hair regrowth in alopecia areata.

Baricitinib is more effective than methotrexate for severe alopecia areata.

A woman's hair grew back with baricitinib treatment, but she developed a temporary hairy tongue that was treated with regular tongue brushing.

Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.

Tofacitinib effectively promotes hair regrowth in children with alopecia areata, but more research on long-term safety is needed.

Baricitinib works better for alopecia areata in patients not previously treated with tofacitinib.

Combining DPCP with PRP doesn't improve hair regrowth in alopecia areata.